Protherics Plc - Report of Foreign Issuer (6-K)
July 07 2008 - 8:43AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
4th July 2008
PROTHERICS PLC
(Translation of Registrant’s Name Into
English)
The Heath Business & Technical Park
Runcorn, Cheshire, W47 4QF England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
X
Form
40-F
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 191(b)(7):
Indicate by check mark whether the registrant by
furnishing the information contained in this form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
of 1934.
Yes
No
X
If “Yes” is marked, indicate below the
file number assigned to the registrant in connection with Rule 12g3-2(b):
82-
.
The Registrant is furnishing a copy of its
announcements as reported to the Company Announcements Office of the London Stock
Exchange.
Lon
don, UK; Brentwood, TN, US:
4
July
2008
-
Protherics PLC ("Protherics" or the "Company"), the
international biopharmaceutical company focused on critical care an
d cancer,
a
nnounces that the
Company
has
today issued 1,741,911 ordinary shares pursuant to
the MacroMed Acquisition Agreement ("Agreement") approved by
shareholders
at the Company's Extraordinary General Meeting
held
on 3 January 2007
and
details of which were
contained in the Company's announcement
dated
7 December 2006
.
Under the terms of the Agreement 10% of the
ordinary
shares issuable upon
the
acquisition of Mac
roMed Inc. were held back for a period of
18 months
from the date of the Acquisition and
have become issuable on the basis that no claims
against the MacroMed
vendors
have arisen over that period.
Accordingly, application has today been made to the UK
Listing Authority of the London Stock Exchange for the listing of 1,741,911
ordinary shares of 2p each in the Company.
The Shares will rank equally with the existing issued
ordinary shares of the Company and are expect
ed to
be admitted to the Official List and
commence trading
on or
around 9
July 2008.
Following admission of the
se
ordinary shares
, the Company's issued
share capital will be 342,159,034
ordinary shares
.
F
or f
urther
i
nformation
please contact
:
|
|
|
Nick Staples
,
Director of Corporate
Affairs
|
|
Julie Vickers, Company Secretary
|
|
|
|
|
Financial Dynamics
- press enquiries
|
|
London:
Ben Atwell, Lara Mott
|
|
New York
:
John Capodanno,
Jonathan Birt
|
|
Or visi
t
www.protherics.com
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
PROTHERICS PLC
|
|
|
|
|
|
|
|
|
|
Date: 4th July 2008
|
|
By:
|
|
/s/ Rolf Soderstrom
|
|
|
|
|
|
Rolf Soderstrom
|
|
|
|
|
|
Finance Director
|
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Jul 2023 to Jul 2024
